Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection

Clinical Immunology

Volumn 106, Issue 2, 2003, Pages 106-115

  Groeneveld, A B J ^a   Tacx, A N ^a   Bossink, A W J ^a   Van Mierlo, G J ^a   Hack, C E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Fever; Infection; Inflammatory host response; Morbidity; Mortality; Septic shock

Indexed keywords

COMPLEMENT COMPONENT C3A; INTERLEUKIN 6; PHOSPHOLIPASE A2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM CULTURE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HOST SUSCEPTIBILITY; HUMAN; IMMUNE STATUS; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROBIAL SENSITIVITY TEST; MORTALITY; MYCOSIS; PARASITEMIA; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEPTIC SHOCK; SPECIES INVASION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037301609     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(02)00025-6     Document Type: Article

References (45)

1. McGowan J.E., Rose R.C., Jacobs N.F., Schaberg D.R., Haley R.W. Fever in hospitalized patients. With special reference to the medical service. Am. J. Med. 82:1987;580-586.
2. Zanetti G., Heumann D., Gerain J., Kohler J., Abbet P., Barras C., Lucas R., Glauser M.P., Baumgartner J.-D. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor and to lipopolysacharide. J. Immunol. 148:1992;1890-1897.
3. Halstensen A., Ceska M., Brandtzaeg P., Redl H., Naess A., Waage A. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J. Infect. Dis. 167:1993;471-475.
4. Boutten A., Dehoux M.S., Seta N., Ostinelli J., Venembre P., Crestani B., Dombret M.-C., Durand G., Aubier M. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am. J. Respir. Crit. Care Med. 153:1996;336-342.
5. Terashima T., Matsubara H., Nakamura M., Sakamaki F., Waki Y., Soeijima K., Tasaka S., Nakamura H., Sayamna K., Ishizaka A., Kanazawa M. Local Pseudomonas instillation induces contralateral lung injury and plasma cytokines. Am. J. Respir. Crit. Care Med. 153:1996;1600-1605.
6. Van der Poll T., Keogh C.V., Buurman W.A., Lowry S.F. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 155:1997;603-608.
7. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.-F., Achong M.K. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101:1998;311-320.
8. Riché F.C., Cholley B.P., Panis Y.H., Laisné M.-J., Briard C.G., Graulet A.-M., Guéris J.L., Valleur P.D. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit. Care Med. 18:2000;433-437.
9. Katja B., Hartmut K., Pawel M., Stefan B., Kox W.-J., Spies C.D. The value of immune modulating parameters in predicting the progression from peritonitis to septic shock. Shock. 15:2001;95-100.
10. 1-antitrypsin and lactoferrin versus clinical variables . Clin. Infect. Dis. 29:1999;398-407.
11. Groeneveld A.B.J., Bossink A.W.J., Van Mierlo G.J., Hack C.E. Circulating inflammatory mediators in patients with fever Predicting bloodstream infection . Clin. Diagn. Lab. Immunol. 8:2001;1189-1195.
12. Hack C.E., De Groot E.R., Felt-Bersma R.J.F., Nuijens J.H., Strack van Schijndel R.J.M., Eerenberg-Belmer A.J.M., Thijs L.G., Aarden L.A. Increased plasma levels of Interleukin-6 in sepsis. Blood. 74:1989;1704-1710.
13. Hack C.E., Nuijens J.H., Felt-Bersma R.J., Schreuder W.O., Eerenberg-Belmer A.J., Paardekooper J., Bronsveld W., Thijs L.G. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am. J. Med. 86:1989;20-26.
14. Calandra T., Gerain J., Heumann D., Baumgartner J.-D., Glauser M.P. High circulating levels of interleukin-6 in patients with septic shock Evolution during sepsis, prognostic value, and interplay with other cytokines . Am. J. Med. 91:1991;23-29.
15. Dofferhoff A.S.M., Bom V.J.J., De Vries-Hospers H.G., Van Ingen J., Van der Meer J., Hazenberg B.P.C., Mulder P.O.M., Weits J. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit. Care Med. 20:1992;185-192.
16. Gardinali M., Padaino P., Vesconi S., Calcagno A., Ciappellano S., Conciato L., Chiara O., Agostoni A., Nespoli A. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Arch. Surg. 127:1992;1219-1224.
17. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119:1993;771-778.
18. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 103:1993;565-575.
19. 2 and cytokines in patients with sepsis. Res. Commun. Mol. Pathol. Pharmacol. 90:1995;413-421.
20. Stöve S., Welte T., Wagner T.O.F., Kola A., Klos A., Bautsch W., Köhl J. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 3:1996;175-183.
21. 2 . Infection. 24:1996;103-108.
22. Damas P., Canivet J.L., De Grootte D., Vrindts Y., Albert A., Franchimont P., Lamy M. Sepsis and serum cytokine concentrations. Crit. Care Med. 25:1997;405-412.
23. Presterl E., Staudinger T., Pettermann M., Lassnigg A., Burgmann H., Winkler S., Frass M., Graninger W. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am. J. Respir. Crit. Care Med. 156:1997;825-832.
24. Arnalich F., Garcia-Palomero E., López J., Jiménez M., Madero R., Renart J., Vazquez J.J., Montiel C. Predictive value of nuclear factor κβ activity and plasma cytokine levels in patients with sepsis. Infect. Immun. 68:2000;1942-1945.
25. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis A marker for prognosis and future therapeutic options . J. Infect. Dis. 181:2000;176-180.
26. Wolbink G.-J., Bossink A.W.J., Groeneveld A.B.J., De Groot M.C.M., Thijs L.G., Hack C.E. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J. Infect. Dis. 177:1998;81-87.
27. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Friedl H.P., Ward P.A. Protective effect of C5a blockade in sepsis. Nat. Med. 5:1999;788-792.
28. Huber-Lang M., Sarma V.J., Lu K.T., McGuire S.R., Padgaonkar V.A., Guo R.-F., Younkin E.M., Kunkel R.G., Ding J., Erickson R., Curnutte J.T., Ward P.A. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166:2001;1193-1199.
29. Bulger E.M., Maier R.V. Lipid mediators in the pathophysiology of critical illness. Crit. Care Med. 28:(Suppl.):2000;N27-N36.
30. Jansen P.M., Eisele B., De Jong I.W., Chang A., Delvos U., Taylor F.B., Hack C.E. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol. 160:1998;475-484.
31. Fronhoffs S., Luyken J., Steuer K., Hansis M., Vetter H., Walger P. The effect of C1 esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med. 26:2000;1566-1570.
32. Zimmerman J.L., Dellinger R.P., Streaube R.C., Levin J.L. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 28:2000;3149-3154.
33. Arndt P., Abraham E. Immunological therapy of sepsis Experimental therapies . Intensive Care Med. 27:2001;S104-S115.
34. Reinhart K., Menges T., Gardlund B., Zwaveling J.H., Smithes M., Vincent J.L., Tellado J.M., Salgado-Remigio A., Zimlichman R., Withingto S., Tschaikowsky K., Brase R., Damas P., Kupper H., Kempeni J., Eiselstein J., Kaul M. for the AFELIMOMAB Sepsis Study Group. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment in hyperinflammatory response during severe sepsis The RAMSES Study . Crit. Care Med. 29:2001;765-769.
35. Remick D., Manohar P., Bolgos G., Rodriguez J., Moldawer L., Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysac charide lethality, but not the lethality of cecal ligation and puncture. Shock. 4:1995;89-95.
36. Bossink A.W.J., Groeneveld A.B.J., Hack C.E., Thijs L.G. Prediction of mortality in febrile medical patients How useful are systemic inflammatory response syndrome and sepsis criteria? Chest. 113:1998;1533-1541.
37. Helle M., Boeije L., De Groot E., De Vos A., Aarden L.A. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids Synovial fluids and sera . J. Immunol. Methods. 138:1991;47-56.
38. 2. Cancer Immunol. Immunother. 41:1995;287-292.
39. O'Grady N.P., Preas H.L. II, Pugin J., Fiuza C., Tropea M., Reda D., Banks S.M., Suffredini A.F. Local inflammatory responses following bronchial endotoxin installation in humans. Am. J. Respir. Crit. Care Med. 163:2001;1591-1598.
40. Bengtsson A., Redl H., Schlag G., Hogase K., Gotze O., Mollnes T.E. Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation. Scand. J. Immunol. 48:1998;509-514.
41. Celik I., Stover C., Botto M., Thiel S., Tzima S., Künkel D., Walport M., Lorenz W., Schwaeble W. Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect. Immun. 69:2001;7304-7309.
42. 2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin Some implications for its functional role . Biochem. J. 306:1995;167-175.
43. desarg regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J. Infect. Dis. 177:1998;1622-1628.
44. Dalrymple S.A., Slatterny R., Krishna M., Lucian L.A., Murray R. Interleukin-6 is required for a protective imnmune reponse to systemic Escherichia coli infection. Infect. Immun. 64:1996;3231-3235.
45. Schröder J., Kahlke V., Staubach K.-H., Zabe P., Stüber F. Gender differences in human sepsis. Arch. Surg. 133:1998;1200-1205.